Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is preparing for the possible FDA approval of its weight loss drug candidate VK2735 ...

Viking's oral VK2735 efficacy was strong, but tolerability issues and high discontinuation rates cloud its competitive edge in the obesity drug market. The market's perception of Viking shifted after ...

The two-time Daytime Emmy winner and Nick Jr. exec said she put a lot of herself into the character Uniqua, whom she called a “ringleader.” By Mike Barnes Senior Editor Janice Burgess, the two-time ...

Eli Lilly is a leader in weight loss drugs, a market that may reach $95 billion by the end of the decade. Viking Therapeutics is heading toward the finish line with a drug that could compete with ...